We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Tilray Brands, Inc. (TLRY - Free Report) closed the most recent trading day at $0.40, moving -2.84% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day. Meanwhile, the Dow gained 1%, and the Nasdaq, a tech-heavy index, added 0.52%.
The company's shares have seen a decrease of 11.24% over the last month, not keeping up with the Medical sector's gain of 3.5% and the S&P 500's gain of 5.95%.
Analysts and investors alike will be keeping a close eye on the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. On that day, Tilray Brands, Inc. is projected to report earnings of -$0.03 per share, which would represent year-over-year growth of 25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $254.8 million, up 10.84% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.01 per share and revenue of $850.75 million, indicating changes of -206.06% and 0%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Tilray Brands, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Tilray Brands, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 164, placing it within the bottom 34% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for Investors
Tilray Brands, Inc. (TLRY - Free Report) closed the most recent trading day at $0.40, moving -2.84% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day. Meanwhile, the Dow gained 1%, and the Nasdaq, a tech-heavy index, added 0.52%.
The company's shares have seen a decrease of 11.24% over the last month, not keeping up with the Medical sector's gain of 3.5% and the S&P 500's gain of 5.95%.
Analysts and investors alike will be keeping a close eye on the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. On that day, Tilray Brands, Inc. is projected to report earnings of -$0.03 per share, which would represent year-over-year growth of 25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $254.8 million, up 10.84% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.01 per share and revenue of $850.75 million, indicating changes of -206.06% and 0%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Tilray Brands, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Tilray Brands, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 164, placing it within the bottom 34% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.